Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 8041 AL 8055

Effectiveness of probiotic supplements on cognitive function in mild cognitive impairment and Alzheimer's disease: A meta-analysis of randomized controlled trials

Peng TR, Lin HH, Tseng TL, Wu TW.

Gen Hosp Psychiatry. 2025 Nov-Dec;97:284-293. doi: 10.1016/j.genhosppsych.2025.11.004. Epub 2025 Nov 11.

Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches

Bereczki E, Mangialasche F, Barbera M, Padilla P, Hara Y, Fillit H, Solomon A, Kivipelto M.

J Prev Alzheimers Dis. 2025 Dec;12(10):100367. doi: 10.1016/j.tjpad.2025.100367. Epub 2025 Oct 27.

Structural and metabolic topological alterations associated with butylphthalide treatment in mild cognitive impairment: Data from a randomized, double-blind, placebo-controlled trial

Han X, Gong S, Gong J, Wang P, Li R, Chen R, Xu C, Sun W, Li S, Chen Y, Yang Y, Luan H, Wen B, Guo J, Lv S, Wei C.

Psychiatry Clin Neurosci. 2025 Jun;79(6):336-343. doi: 10.1111/pcn.13812. Epub 2025 Mar 31.

The Biological Intersection Between Chemotherapy-Related Cognitive Impairment and Alzheimer Disease

Torre M, Zanella CA, Feany MB.

Am J Pathol. 2025 Nov;195(11):2088-2101. doi: 10.1016/j.ajpath.2024.12.013. Epub 2025 Jan 23.

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K.

J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1.

Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis

Jeong SY, Suh CH, Lim JS, Shim WH, Heo H, Choi Y, Kim HS, Kim SJ, Lee JH.

Neurology. 2025 Apr 22;104(8):e213483. doi: 10.1212/WNL.0000000000213483. Epub 2025 Mar 19.

Efficacy of Add-On Agomelatine on Agitation, Aggression, and Neuroprotection in Alzheimer's Disease: A Randomized, Blinded, Controlled Trial

Kargar A, Fetratjoo DH, Moattar R, Tarki A, Golsokhan A, Pouyan N, Amjadi-Goojgi Z, Mostafaei H, Kakeri F, Zendehbad AS, Lima BS, Esmaily H, Noroozian M.

Am J Geriatr Psychiatry. 2025 Aug;33(8):819-834. doi: 10.1016/j.jagp.2025.03.001. Epub 2025 Mar 20.

Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial

Squitti R, Benussi A, Fostinelli S, Geviti A, Rivolta J, Ventriglia M, Micera A, Rongioletti M, Ghidoni R, Santilli M, Granzotto A, Albanese A, Binetti G, Sensi SL, Borroni B.

Biomolecules. 2025 Sep 1;15(9):1268. doi: 10.3390/biom15091268.

Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP)

Luchsinger JA, Devanand D, Goldberg TE, Cammack S, Hernández-Santiago G, Oishi K, Jagust W, Baker S, Landau S, Yenokyan G, Betz J, Mayers S, Eyzaguirre LM, Hanley D; MAP Study Group.

Alzheimer Dis Assoc Disord. 2025 Apr-Jun 01;39(2):123-133. doi: 10.1097/WAD.0000000000000677. Epub 2025 May 28.

Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial

Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, Bhattacharyya S, Jafari H, Kaur S, Kandangwa P, Carter B, Aarsland D.

Age Ageing. 2025 May 31;54(6):afaf149. doi: 10.1093/ageing/afaf149.

Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease

Stroud J, Cummings JL, Chumki SR, Such P, Wang D, Palma AM, Zhang Z, Brubaker M, Grossberg GT.

Curr Med Res Opin. 2025 Aug;41(8):1523-1534. doi: 10.1080/03007995.2025.2552278. Epub 2025 Sep 5.

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial

Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M.

Drugs. 2025 Nov;85(11):1455-1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28.

Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms

Bayo Jimenez MT, Rivas-García L, Sánchez-González C, Grosso G, Lipari V, Vera-Ramírez L, Battino M, Giampieri F, Quiles JL, Forbes-Hernández TY.

Int J Mol Sci. 2025 Oct 31;26(21):10631. doi: 10.3390/ijms262110631.

Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial

Shah A, Estilo A, Sheridan PL, Kalu U, Chen D, Chang D, Slomkowski M, Lee D, Hefting N, Hobart M, Behl S, Such P, Brubaker M, Grossberg GT.

CNS Drugs. 2025 Oct;39(10):1011-1023. doi: 10.1007/s40263-025-01200-9. Epub 2025 Jul 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias